Skip to main content
Figure 1 | Arthritis Research & Therapy

Figure 1

From: Unmet needs in rheumatoid arthritis

Figure 1

Etanercept in active rheumatoid arthritis (TEMPO trial): ACR responses at 52 weeks. *P < 0.01, P < 0.0001, versus placebo; P < 0.05, §P < 0.0001, versus etanercept. ACR, American College of Rheumatology; MTX, methotrexate; TEMPO, Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes. Reprinted with permission [16].

Back to article page